#### Circulation of SARS-CoV-2 and co-infection with 1

# Plasmodium falciparum in Equatorial Guinea

3

2

4	Diana López-Farfán <sup>1</sup> , Policarpo Ncogo <sup>2,3</sup> , Consuelo Oki <sup>4</sup> , Matilde Riloha <sup>4</sup> , Valero Ondo <sup>4</sup> ,						
5	Pablo Cano-Jiménez <sup>5</sup> , Francisco José Martínez-Martínez <sup>5</sup> , Iñaki Comas <sup>5,6</sup> , Nerea						
6	Irigoyen <sup>7</sup> , Pedro Berzosa <sup>3,8</sup> , Agustín Benito Llanes <sup>8</sup> & Elena Gómez-Díaz <sup>1</sup>						
7							
8	<sup>1</sup> Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de						
9	Investigaciones Científicas (IPBLN, CSIC), Granada, Spain.						
10	<sup>2</sup> Instituto de Salud Carlos III, Madrid, Spain.						
11	<sup>3</sup> Fundación CSAI. Madrid, Spain.						
12	<sup>4</sup> Ministerio de Sanidad y Bienestar Social, Malabo, Equatorial Guinea.						
13	<sup>5</sup> Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas						
14	(IBV, CSIC), Valencia, Spain.						
15	<sup>6</sup> CIBER in Epidemiology and Public Health, Madrid, Spain						
16	<sup>7</sup> Division of Virology, Department of Pathology, University of Cambridge, Cambridge,						
17	UK.						
18	<sup>8</sup> Centro Nacional de Medicina Tropical. CIBERINFEC, Instituto de Salud Carlos III.						
19	Madrid, Spain.						
20							
21	* Corresponding author:						
22	E-mail: diana.lopez@ipb.csic.es (DL-F)						
23							

Keywords: COVID-19, malaria, co-infection, coronavirus, Africa, genomic surveillance 24 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25

# 26 Abstract

27 The impact of COVID-19 in Africa has been a big concern since the beginning of the pandemic. However, low incidence of COVID-19 case severity and mortality has been 28 reported in many African countries, although data are highly heterogeneous and, in some 29 regions, like Sub-Saharan Africa, very scarce. Many of these regions are also the cradle 30 of endemic infectious diseases like malaria. The aim of this study was to determine the 31 32 prevalence of SARS-CoV-2, the diversity and origin of circulating variants as well as the frequency of co-infections with malaria in Equatorial Guinea. For this purpose, we 33 conducted antigen diagnostic tests for SARS-CoV-2, and microscopy examinations for 34 35 malaria of 1.556 volunteers at six health centres in Bioko and Bata from June to October 2021. Nasopharyngeal swab samples were also taken for molecular detection of SARS-36 COV-2 by RT-qPCR and whole genome viral sequencing. We report 3.0% of SARS-37 CoV-2 and 24.4% of malaria prevalence over the sampling in Equatorial Guinea. SARS-38 CoV-2 cases were found at a similar frequency in all age groups, whereas the age groups 39 40 most frequently affected by malaria were children (36.8% [95% CI 30.9-42.7]) and teenagers (34.7% [95% CI 29.5-39.9]). We found six cases of confirmed co-infection of 41 malaria and SARS-CoV-2 distributed among all age groups, representing a 0.4% 42 43 frequency of co-infection in the whole sampled population. Interestingly, the majority of malaria and SARS-CoV-2 co-infections were mild. We obtained the genome sequences 44 of 43 SARS-CoV-2 isolates, most of which belong to the lineage Delta (AY.43) and that 45 46 according to our pandemic-scale phylogenies were introduced from Europe in multiple occasions (7 transmission groups and 17 unique introductions). This study is relevant in 47 providing first-time estimates of the actual prevalence of SARS-CoV-2 in this malaria-48

endemic country, with the identification of circulating variants, their origin, and theoccurrence of SARS-CoV-2 and malaria co-infection.

51

# 52 Introduction

53 The coronavirus disease 19 (COVID-19) has caused more than 767 million cases and 6,9 million deaths worldwide. However, only a small proportion of these (around 9.5 million 54 cases [1.24%] and 175,339 deaths [2.52%]) have occurred in Africa (data as of July 2023, 55 56 WHO COVID-19 Dashboard) (1). Moreover, inside Africa, the distribution of cases has been uneven. Most of the reported cases are from a few Northern and Southern countries 57 like South Africa (4.0 million cases), Morocco (1.27 million cases) and Tunisia (1.15 58 million cases). In comparison, only 634,161 cases account for Central African countries. 59 These data suggest country-specific factors such as reduced transmission or limited 60 61 testing, raising questions about the real impact of the pandemic in Central African countries. 62

Genomic SARS-CoV-2 surveillance has been vital in monitoring the emergence, 63 64 evolution and spread of different variants of concern (VOC). Indeed, several VOC, such as Alpha, Beta, Delta and Omicron, were first detected on the African continent or have 65 spread extensively on it (2–4). Despite the heterogeneous pandemic across Africa, most 66 67 countries have reported multiple waves of infection (4). Genomic sequencing has also revealed that each wave has been dominated by a different lineage (4,5). Within Africa 68 regional viral population diversity has been observed in the first and second waves and, 69 to a lesser extent, in the third wave. In North and Southern Africa, the first and second 70 71 waves were dominated by Beta (B1) and Alpha lineages, replaced by Delta and Omicron 72 in the third and fourth waves, respectively. However, different lineages in West, East and Central Africa have dominated the first, second and third waves (4). In addition, other 73

minor lineages have been detected co-circulating and contributing to epidemic waves in 74 75 all regions of the continent (4,6). In this context, characterising the local diversity of 76 SARS-CoV-2 variants country by country becomes critical. Equatorial Guinea is located on the west coast of Central Africa and consists of two parts, 77 78 the mainland and an insular region (i.e., Bioko is the main island). As of April 2023, this country had reported 17,130 cases and 183 deaths, most of them from the insular region 79 (77,2%) (7). Like in other African countries, data about the prevalence of SARS-COV-2 80 infection in Equatorial Guinea is still scarce. Indeed, to our knowledge, no representative 81 studies exist which evaluate the prevalence of SARS-COV-2 in this country. 82 After Equatorial Guinea confirmed its first case of COVID-19 community transmission 83 on March 14, 2020, there have been five waves (7). A genomic analysis of SARS-COV-84 2 sequences revealed that the first wave from April to July 2020 was dominated by the 85 early lineage B.1.192, the second wave from January to April 2021 was dominated by the 86 Beta variant (B.1.351), and the third wave began during July 2021 with the Delta variant 87 88 (AY.43) (5). To date, there are deposited 213 SARS-CoV-2 whole genome sequences from Equatorial 89

Guinea on the GISAID database (8). These data correspond, however, to 1.2% of reported cases, which is far from the World Health Organization (WHO) recommendation to sequence at least 5% of COVID-19 cases by country (9). Hence, there is a need to increase the number of SARS-CoV-2 genomes to sequence for a complete assessment of the diversity of variants circulating in the country.

Apart from the direct mortality impact of COVID-19, the pandemic has also resulted in a
worsening crisis in controlling several endemic diseases in Africa (10–12). During the
first year of the COVID-19 pandemic, malaria cases and deaths in Africa increased from
213 to 228 million cases and from 534,000 to 602,000 deaths (15 million more cases and

68,000 more deaths). This was mainly due to disruption in malaria interventions (13), 99 100 reaching the worst-case scenario projected at the beginning of the pandemic (14). During 101 2021, the increase of malaria cases continued but was less marked (2 million more cases) 102 while deaths remained stable (13). This was possible due to the efforts of countries and partners that provided additional funding to deliver essential malaria services (13). 103 104 Besides these collateral effects, the circulation of COVID-19 in malaria-endemic 105 countries raises the possibility of co-infection. The frequency and consequences of coinfection at the population level have been assessed in eight African (15,16,25,26,17–24) 106 107 and one Indian (27) malaria-endemic countries. However, these studies have shown very 108 heterogeneous results depending on the study design and the population or subpopulation

109 sampled (S1 Table in S1 Text).

Equatorial Guinea is among the moderate to high malaria transmission countries in the African Region, which accounts for 95% of cases and 96% of malaria deaths globally. To date, no study has examined the occurrence and frequency of SARS-COV-2 and malaria co-infection.

114 To fill these gaps, in this work, we conducted a cross-sectional study of 1,556 volunteers 115 at six health centres, three in Bioko (island) and three in Bata (mainland), from June to 116 October 2021. All subjects were tested for SARS-CoV-2 by rapid antigen diagnostic tests and for malaria by microscopy. Moreover, swab samples were also taken for SARS-CoV-117 2 RT-qPCR and whole genome viral sequencing. To our knowledge, this is one of the 118 119 largest SARS-CoV-2 epidemiological studies conducted in Sub-Saharan Africa. This is also the first to evaluate SARS-COV-2 and malaria co-infection in this endemic malaria 120 country. 121

122

# 123 Methods

124

#### 125 Ethics

This protocol was revised by members of the ISCIII/FCSAI at Equatorial Guinea, 126 approved by the Spanish National Research Council (CSIC), the Ethics Committee of 127 Biomedical Research in Andalusia (CCEIBA), and the technical committee of the 128 129 Ministry of Health and Social Welfare of Equatorial Guinea. The field procedures were carried out by the technical staff of the National Malaria Programme of the Ministry of 130 Health and Social Welfare of Equatorial Guinea. The protocol is in conformity with the 131 declaration of Helsinki and all international regulations about the ethical principles in 132 biomedical research involving human subjects. SARS-CoV-2 and malaria-positive 133 individuals were provided with treatment and assisted by medical professionals. During 134 135 the screening, local authorities, health centres and volunteers were informed about the objectives of the study and the protocols performed. 136

137

### 138 Study design

139 This study was conducted at six health centres in Equatorial Guinea, three located at Bioko Island (Hospital Regional de Malabo, Centro de Salud Buena Esperanza and 140 141 Centro de Salud de Campo Yaundé) and three located at the mainland city of Bata (Centro de Salud María Rafols, Centro de Salud La Libertad and Hospital Regional de Bata). 142 1,556 volunteers were enrolled at the six health centres from <sup>1st</sup> June to 4<sup>th</sup> October 2021 143 144 (S2 Table in S1 text). Demographic and clinical information collected included age, sex, temperature, symptomatology and pregnancy state. Since COVID-19 vaccination started 145 146 on March 2021, only non-vaccinated volunteers were eligible for the study. 147 Prior to taking any samples, participants were required to sign the informed consent form

148 created for the study. For each participating subject, one drop of blood was obtained by

capillary puncture of the fingertip. This blood was used for malaria detection by microscopy. When there was consent, a nasopharyngeal sample was also collected for rapid antigen detection of SARS-CoV-2. For SARS-CoV-2 positive antigen test volunteers, a second nasopharyngeal sample was taken, and the swab was stored in prefilled tubes containing 0.5 mL of inactivating lysis buffer (AVL, QIAGEN) for molecular testing of SARS-CoV-2 and whole genome viral sequencing. These samples were kept at 4°C for 24h and at -20°C or -80°C for extended storage and subsequent analysis.

156

### 157 Malaria and SARS-CoV-2 diagnosis

Malaria was detected by microscopy following standard methods (28). Blood thick
smears were screened for *Plasmodium falciparum* asexual and gametocyte stages in the
blood.

Antigen detection of SARS-CoV-2 was performed from individual nasal swabs samples 161 using the Panbio<sup>™</sup> COVID-19 Ag Rapid Test (Abbot) following the manufacturer's 162 163 instructions. For SARS-COV-2 molecular detection, RNA was extracted from 140 µL of the AVL preservative solution using the QIAamp viral RNA extraction kit (QIAGEN) 164 165 following the manufacturer's instructions. RT-qPCR analysis was performed using the 166 one-step Direct SARS-CoV-2 Realtime PCR Kit (Vircell S.L) following the 167 manufacturer's instructions, reactions were performed in 20 µL final volume (5 µL of RNA sample and 15 µL of RT-PCR mix) using a CFX96 Real-Time PCR Detection 168 System (Bio-Rad, Hercules, CA, USA). Cycle threshold (Ct) values were analysed using 169 the BIORAD CFX manager software. Gene targets identified with this kit were the 170 171 nucleocapsid (N), the envelope (E) and the human RNase P. Samples were considered positive when the N and E target genes had a cycle threshold (Ct) < 40. Positive and 172 negative controls were always included. 173

174

# 175 Statistical analysis

Association between variables was tested with the Wilcoxon Sum Rank tests (forcontinuous quantitative variables) and the Kruskal-Wallis chi-squared test.

178

# 179 Whole genome sequencing and phylogenetic analysis

RNA from SARS-CoV-2 positive samples with a Ct value  $\leq 35$  was sent for sequencing 180 181 to the Instituto de Biomedicina de Valencia (IBV-CSIC). RNA was retrotranscribed into cDNA, and SARS-CoV-2 complete genome amplification was performed in two 182 multiplex PCR, accordingly to openly available protocol developed by the ARTIC 183 network5 using the V4.1 multiplex primers scheme (artic-network n.d.). Two resulting 184 amplicon pools were combined and used for library preparation. Genomic libraries were 185 186 constructed with the Nextera DNA Flex Sample Preparation kit (Illumina Inc., San Diego, 187 CA) according to the manufacturer's protocol with five cycles for indexing PCR. Whole genome sequencing was performed in a MiSeq platform  $(2 \times 150 \text{ cycles paired-end run})$ 188 189 Illumina). Sequences obtained went through an open-source bioinformatic pipeline based 190 on IVAR6 (29). The different steps of the pipeline are as follows: 1) removal of human 191 reads with Kraken (30); 2) filtering of the fastq files using fastp v 0.20.1 (31) (arguments: -cut tail, -cut-window-size, -cut-mean-quality, -max len1, -max len2); 3) mapping and 192 193 variant calling using IVAR v 1.2; and 4) quality control assessment with MultiQC (32). 194 Consensus sequences generated by this pipeline were aligned against the SARS-CoV-2 195 reference sequence (33) with MAFFT (34). Problematic positions were masked using the mask alignment.py script from the repository maintained by Rob Lanfear7. Lineages and 196 197 clade nomenclature were assigned using Pangolin (35) and Nexclade online tool (36).

The phylogenetic tree was generated with Nextclade v2.5.08, downloaded in JSONformat and visualised using Auspice v2.37.3 online tool9 (37,38).

200

# 201 Genome-based epidemiological analysis

A genome-based epidemiological analysis was performed on the sequenced Guinea 202 203 Equatorial samples following the pipeline described in Martínez-Martínez et al (39). We used a pandemic-scale phylogenomics analysis tool called UShER (40) to place the 204 newly-sequenced samples in a prebuilt phylogeny. For this purpose, we downloaded an 205 206 existing SARS-CoV-2 phylogeny (eTree) composed of 15.649.343 sequences uploaded 207 in GISAID (8) on July 27th, 2023 from the UCSC ftp server (ftp:apache/cgi-208 bin/hgPhyloPlaceData/wuhcor1). This method avoids subsampling the dataset by the 209 country of origin or the sampling date, maintaining the broadest possible context.

Using Robert Lanfear's global\_profile\_alignment.sh (41), we aligned the Guinea Equatorial sequences against the Wuhan reference sequence (MN908947.3). We used the faToVcf tool from the UShER toolbox to obtain the VCF file, and used this file as input along with the eTree to place the new 43 sequences.

214 To speed up the analysis, we extracted the Beta and Delta variants' clades from the eTree 215 using matUtils (42) after identifying the parental nodes using the Taxonium viewer (43). 216 Finally, using a custom code developed in R, we identified the likely country/region of 217 origin and the period of the introductions. To do so, we first defined 3 possible categories for our sequences: transmission group, if they fell in a node in which >60% samples were 218 from Equatorial Guinea; unique sequence, if they fell in a node with lower presence of 219 220 the country and the length of their branches is greater than 0; and unclassified, if they had no branch length. Then, we searched for the closest sequence with the minimal genetic 221 distance in SNPs that was collected within a period between the 3 months prior to the 222

sampling date, and the sampling date minus 10 days. All the commands used in this
analysis are available at the GitLab repository along with the custom code
(https://gitlab.com/tbgenomicsunit/covid-guinea).

226

#### 227 Ethics Statement

The studies involving human participants were reviewed and approved by Ethics Committee of the Spanish National Research Council (CSIC), the Ethics Committee of Biomedical Research in Andalusia (CCEIBA), and the technical committee of the Ministry of Health and Social Welfare of Equatorial Guinea. Participants were required to sign the informed consent form created for the study. As the study involved children, a signed declaration of conformity for participating was obtained from their parents and/or legal representatives.

235

# 236 **Results and Discussion**

Compared to the rest of the world, the impact of COVID-19 in Africa has been relatively 237 low in terms of severe disease incidence and mortality rate. Several specific socio-238 239 ecological and economic factors (i.e., warm weather, younger population, lower population density and mobility, limited testing capacity and previously trained immunity 240 241 by past infectious diseases) have been proposed to explain the apparent lower transmission (44,45). Other reports, however, suggest that this impact has been vastly 242 underestimated, especially in low-income countries, due to insufficient testing and 243 244 uneven genomic surveillance. This is probably the case in Equatorial Guinea, where no comprehensive studies assess the prevalence of SARS-CoV-2 and the number of viral 245 genomes available is still very low. 246

Apart from the noticeable direct effects, the COVID-19 pandemic severely affected the 247 248 global fight against several endemic infectious diseases, namely VIH, tuberculosis and malaria, mainly because of an interruption and reduction in their control programmes 249 250 (10–12). But recent data points towards a more direct biological interaction between these diseases In the case of malaria, it has been suggested that severity of COVID-19 infection 251 252 in malaria-endemic regions may be influenced by co-infection or previous malaria 253 exposure (20,27). Some studies also suggested a possible cross-immunity due to common immunodominant epitopes between the malaria parasite and SARS-CoV-2 (46-48). 254 Prevalence studies of SARS-CoV-2 and co-infection with malaria in sub-Saharan 255 256 countries are therefore essential to understand the real impact of the pandemic in the African continent. 257

258 This is the first comprehensive study of SARS-CoV-2 prevalence in Equatorial Guinea 259 and the first to evaluate malaria co-infection. For this purpose, 1,556 volunteers were recruited at six Equatorial Guinea health centres for four months in 2021 (from June to 260 261 October) (S2 Table in S1 Text). The study was conducted in three health centres on 262 Bioko Island (the site of the country capital, Malabo) and three health centres in the mainland city of Bata. Of the participants, 72.6% were female and 27.4% were male. 263 264 Samples were distributed to four age groups as follows: A. 5-12 years old (16.8%), B. 13-20 years old (20.8%), C. 21-40 years old (46.2%) and D. >40 years (16.3%). The 265 distribution of positive cases by age and gender is detailed in Table 1. 266

269	Age group	Gender <sup>a</sup>	Non-infected	SARS-CoV-2	Malaria	SARS-CoV-2	Subtotal	Total
270	(years)					& malaria		
271	A 5 10	F	89 (62.7%)	4 (2.8%)	49 (34.5%)	0	142 (54.4%)	
271	A. 5-12	Μ	69 (58,0%)	5 (4.2%)	47 (39.5%)	2 (1.7%)	119 (45,6%)	261 (16.8%)
272	D 12 20	F	149 (61.1%)	8 (3.3%)	84 (35.0%)	1 (0.4%)	240 (74.3%)	
273	B. 13-20	М	54 (65.1%)	1 (1.2%)	28 (33.7%)	0	83 (25.7%)	323 (20.8%)
274	C 21 40	F	444 (79,1%)	11 (2.0%)	108 (19.2%)	2 (0.4%)	561 (78,0%)	
271	C. 21 <b>-</b> 40	Μ	128 (81,0%)	9 (5.7%)	21(13.3%)	0	158 (22.0%)	719 (46.2%)
275	D > 40	F	152 (82.0%)	5 (2.7%)	30 (16.1%)	1 (0.5%)	186 (73.5%)	
276	D. >40	М	52 (77.6%)	3 (4.5%)	12 (17.9%)	0	67 (26.5%)	253 (16.3%)
277	<u> </u>	F	834 (67.9%)	28 (2.5%)	271 (24.0%)	4 (0.3%)	1.129 (72.6%)	
	Subiolal	Μ	303 (71,0%)	18 (4.2%)	108 (25.3%)	2 (0.5%)	427 (27.4%)	
278	Total		1.137 (73.1%)	46 (3.0%)	379 (24.4%)	6 (0.4%)		1.556

268 Table 1. Demographic characteristics and distribution of positive cases in the whole sampled population by age and gender.

279

280 Data are presented as n (%).

<sup>a</sup> F: female; M: male

For this sampling period and subjects, a total of 46 individuals tested positive by SARS-283 284 CoV-2 antigen rapid diagnostic tests, resulting in an overall prevalence of 3.0% (95% CI 2.1-3.8). However, most of the positives were in the health centres of Bioko Island, 285 resulting in a local prevalence of 6.7% (43 positives out of 643 samples) (S2 Table in S1 286 Text). This agrees with the official data from Equatorial Guinea authorities reporting that 287 most SARS-CoV-2 cases were from Bioko Island (7), the site of the capital. SARS-CoV-288 289 2 positive cases were found at similar prevalence in all age groups (Fig 1A) and there 290 were no significant differences between males and females (W = 39812, *p*-value = 0.07) (Fig 1B). However, a temporal trend for SARS-CoV-2 positives increased progressively 291 292 over the sampling period to reach a peak of 10% of prevalence in September 2021 (Fig 2). This trend agrees with the official reports for this country that recorded 4,739 COVID-293 19 cases by September 2021 (49), coinciding with our sampling period with a peak of 294 295 cases. Regarding the symptomatology of these cases, most of the SARS-CoV-2 positive 296 cases were mild symptomatic (91.3%), with fever as the most common symptom (S3 and 297 S4 Tables in S1 Text).

298

#### Fig 1. Prevalence of SARS-CoV-2 and malaria cases by age group and gender.

300 (A) Prevalence by age group. (B) Prevalence by gender.

#### 301 Fig 2. Prevalence of SARS-CoV-2 and malaria over the study period.

302

Nasopharyngeal swabs available of 43 SARS-CoV-2 positive samples were confirmed positive by RT-qPCR with high viral loads, and cycle threshold values were in the range of 7-29. The RNA of these 43 PCR-positive samples was sent for whole genome sequencing. After genome assembly and quality control, good quality genomes were obtained from 40 samples and medium/low quality genomes from three samples. All the

sequences were assigned to lineages using the dynamic lineage classification method, 308 309 Phylogenetic Assignment of Named Global Outbreak Lineages (PANGOLIN) (35). 310 Phylogenetic analysis revealed that most of the sequences belonged to the lineage AY.43 (38 samples), however, other minor lineages were found, like AY.36 (3 samples) and 311 B.1.351 (2 samples) (Fig 3 and S5 Table in S1 text). Our results are in line with a recent 312 genomic study that described the SARS-CoV-2 lineages for the first three waves of the 313 314 pandemic in Equatorial Guinea from February 2020 to October 2021 (5). That study reported that the first wave from April to July 2020 was dominated by the early lineage 315 B.1.192, the second wave from January to April 2021 was caused by the Beta VOC 316 317 (B.1.351), and the third wave that began in July 2021 was dominated by the Delta VOC 318 (AY.43).

319

#### 320 Fig 3. Phylogenetic tree with the 43 new SARS-CoV-2 genomes from Equatorial

**Guinea.** Equatorial Guinea genomes placed on a reference tree of 1,495 published genomes from all over the world. Phylogenetic tree generated with Nextclade online software v2.5.0 (https://clades.nextstrain.org) (accessed on 01 Jun 2023) and visualized using Auspice v2.37.3 (https://auspice.us/).

325

Our sampling period began in June 2021, when a few positive cases were detected and coincided with the end of the second wave (**Fig 2**). From the end of June to the first half of July, the two genomes available were identified as Beta VOC (B.1.351). The lineage B.1.351 was first identified in South Africa in September 2020 and subsequently defined as a variant of concern (VOC) (3). Since then, it spread to other African countries (50). The earliest sequence of this lineage reported from Equatorial Guinea was in January 2021 (51).

However, the peak of our sampling mostly overlaps with the third wave of the pandemic, between August and September 2021 (**Fig 2**). For that period, most isolated sequences were identified as the Delta variant (AY.43), the VOC that dominated the third wave in Equatorial Guinea. Delta variant was first detected in India in late 2020 (52), from where it was spread to more than 170 countries, including 37 African territories (4). It has been reported that most of the introductions of this variant into Africa (72%) can be attributed to India (4).

The other minor lineage found in this study was AY.36, corresponding to samples collected at the end of August. This is an uncommon Delta lineage that was dominant in Nigeria by June-August 2021 (80% cases) but that represented less 0.5% of Delta cases globally as of September 2021 (6). Its introduction in Nigeria was inferred due to a single introduction during April 2021 and the subsequent spread in the country (6).

345 To better determine the likely origin and introduction period of the Equatorial Guinea sequenced samples, we performed a genome-based epidemiological analysis using 346 pandemic-scale phylogenies (53). The results are summarized in Fig 4 and Table S6, our 347 script identifies 17 unique introductions and 7 transmission groups or clusters, whereas 348 11 out of 43 samples remain unclassified. Regarding the origin of the introductions, both 349 350 the transmission groups and unique introductions are mostly of European origin (71.4%, 351 5 out of 7, and 47.1%, 8 out of 17; respectively), in these cases we cannot identify the 352 exact country since many potential origins were found.

353

#### Fig 4. Origin and introduction period of the Equatorial Guinea sequenced samples.

355 (A) Dot plots display introduction periods for transmission groups and unique sequences.

Each dot and its segment represent an introduction and its estimated time interval of

entrance in the country, coloured by the origin. (B) Pie charts represent the proportion ofintroductions for transmission groups (top pie) and unique introductions (bottom pie).

359

In those cases, where the country of origin was identified, we found one transmission 360 group from the United Kingdom (UK) and another from Spain. Concerning 9 unique 361 introductions identified by country, they come from France (4/17, 23.5%), UK (3/17, 362 17.6%), Spain (1/17, 5.9%) and Denmark (1/17, 5.9%). The introductions from Spain 363 correspond to the three AY.36 samples, the two Beta (B.1.351) samples came from UK 364 and France, while the 27 identified AY.43 samples belong to Europe (16/27), France 365 366 (7/27), UK (3/27) and Demark (1/27). Collectively, these results point to that the introduction of SARS-CoV-2 to Equatorial Guinea was mainly from outside Africa, not 367 368 from neighbouring countries.

Regarding the estimated time interval of the introductions, both Beta introductions present a wider interval when compared with Delta, with a range of 2 to 3 months of uncertainty (**Fig 4**). However, this may be due to the large-scale sequencing effort of Delta compared to Beta (~39 K Beta sequences vs. ~ 5 M Delta sequences in GISAID). In our analysis, most Delta introductions occurred between mid-July and mid-September, in concordance with the Delta wave seen at a global scale.

In relation to malaria incidence in Equatorial Guinea, 379 individuals were positive by microscopy out of 1,556 tested (24.4% [95% CI 22.2-26.5]). No significant sex difference was observed (W = 226149, *p*-value = 0.6) (**Fig 1B**). However, there were significant differences between age groups in malaria prevalence (Kruskal-Wallis chi-squared = 64.812, df = 3, *p*-value < 0.001), with malaria mainly affecting children aged below 12 years (36.8% [95% CI 30.9-42.7]) and teenagers between 13-20 years old (34.7% [95% CI 29.5-39.9]) (**Fig 1A**). The majority of the malaria-positive individuals were

symptomatic (92,3%), and the most common symptom was fever (≥37.5), but also
included other mild to moderate symptoms such as headache, weakness, muscle and joint
pain, cough, dizziness, vomiting, diarrhoea and anorexia (S3 and S4 Tables in S1 text).
No comorbidities were reported among the malaria-positive cases.

When considering these two diseases together, we report six cases of confirmed SARS-386 CoV-2 co-infection with malaria. Of them, two were children (8 and 10 years old), one 387 388 was a teenager (14 years old), and three were adults (25, 33 and 41 years old) (Table 1). Most of the co-infections were detected during the peak of SARS-CoV-2 cases in 389 September 2021 (Fig 2). The sequenced co-infection cases were the dominant lineage 390 391 AY.43 (4 samples) and B.1.351 (1 sample) (S5 Table in S1 Text). One case was not sequenced because the swab sample could not be obtained. Five co-infection cases were 392 393 symptomatic, the symptoms registered for three cases were mild and included fever, 394 weakness, headache and dizziness. For the other two cases the symptoms were not specified (S3 and S4 Tables in S1 Text). 395

396 The overall co-infection prevalence reported in this study is low, 0.4% (6/1,556), 397 however, if we calculate the co-infection prevalence among the malaria-positive subpopulation, it corresponds to the 1.6% (6/379), and the co-infection prevalence among 398 399 the COVID-19 subpopulation is 13% (6/46). One possible explanation for the low rate of co-infections in our study could be the small sample size for the age group of adults >40 400 years (16.3%, 253/1,556) and children of 5-12 years (16.8%, 261/1,556), the groups most 401 affected by COVID-19 and malaria, respectively. Indeed, in our previous study carried 402 403 out in Burkina Faso, most of the co-infections were detected in children and teenagers (15), while in another study of Uganda, the highest prevalence of co-infection was in the 404 405 age groups of 0-20 years and above 60 years (20).

Apart from this study, SARS-CoV-2 and malaria co-infection population studies have 406 407 been conducted on nine malaria-endemic countries with heterogeneous results depending on the study design and the population or subpopulation studied (S1 Table in S1 Text). 408 409 Most studies have evaluated malaria co-infection prevalence among COVID-19 confirmed patients reporting a wide range of prevalence from 0.63% to 100% (17-410 411 21.23.26). Among the few studies that have analysed a random population sample, the 412 low co-infection prevalence that we found in Equatorial Guinea (0.4%) is in the range with what has been reported from Nigeria (0.32%) (16), India (0.73%) (27), Burkina Faso 413 (1.9%) (15), Angola (1.9%) (25) and Gabon (2.2%) (24). 414

415 Finally, the low co-infection rate in this and other studies is supported by our previous work in which we explored "in vitro" co-infection of human erythrocytes by Plasmodium 416 417 and SARS-CoV-2. In that study, we reported a low entry of SARS-CoV-2 and a negligible 418 interaction with *Plasmodium falciparum*, so the presence of either pathogen does not affect SARS-CoV-2 or *Plasmodium* infection (54). Our findings in mature erythrocytes 419 420 were in contrast to other studies that reported direct SARS-CoV-2 infection of human 421 erythroid progenitors causing impaired haemoglobin homeostasis, anaemia and other coagulopathies observed in COVID-19 patients (55,56). 422

423 The low SARS-CoV-2 prevalence reported in Equatorial Guinea and the low case severity would support the hypothesis of protection by cross-immunity or trained immunity due 424 to co-occurring endemic diseases such as malaria (46-48). In this study, however, we 425 cannot conclude the consequences of malaria and COVID-19 co-infection since the 426 clinical course for co-infection cases was not systematically recorded. Some other studies 427 have addressed the clinical consequences of malaria and COVID-19 co-infection but with 428 contradictory results. Recent retrospective studies of COVID-19 patients have found that 429 malaria co-infection is associated with prolonged hospitalisation (26) and had greater 430

mortality risk compared with just SARS-CoV-2 infection (23). However, other studies
report that patients with SARS-CoV-2 and malaria did not seem to have a worst disease
outcome, but previous malaria exposure seems to be related to less frequency of severe
COVID-19 (20). In another study, COVID-19 patients co-infected with malaria had
significantly faster recovery compared to those not co-infected (27). All this considered,
additional retrospective and prospective studies are required to better understand the
clinical implications of SARS-CoV-2 and malaria co-infections.

438

# 439 Conclusion

440 The present study expands on the limited knowledge about COVID-19 prevalence in 441 Central Africa. Our results provide further insights into SARS-COV-2 variant circulation. transmission and evolution in Africa, and confirmed that by June to October 2021, the 442 Delta variant AY.43 was dominating the SARS-CoV-2 infections in Equatorial Guinea, 443 together with a few minor variants. This study also challenges the assumption of Africa 444 as a source of new variants that subsequently spread globally. Finally, we report SARS-445 446 CoV-2 and malaria co-infection cases but at low frequency in the population. Importantly, co-infection cases did not worsen symptoms or severity. 447

448

# 449 Acknowledgments

We would like to thank all volunteers who participated in this study and the local authorities and communities in Equatorial Guinea for their support. We also thank the IPBLN and IBV core facilities for their support to project activities.

453

# 454 **References**

455	1.	World Health Organization. WHO COVID-19 Dashboard [Internet]. [cited 2023
456		Jul 28]. Available from: https://covid19.who.int/
457	2.	Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529) - variant of concern
458		- molecular profile and epidemiology: A mini review. Eur Rev Med Pharmacol
459		Sci. 2021;25(24):8019–22.
460	3.	Tegally H, Wilkinson E, Lessells RJ, Giandhari J, Pillay S, Msomi N, et al.
461		Sixteen novel lineages of SARS-CoV-2 in South Africa. Nat Med [Internet].
462		2021;27(3):440-6. Available from: http://dx.doi.org/10.1038/s41591-021-01255-
463		3
464	4.	Tegally H, San JE, Cotten M, Moir M, Tegomoh B, Mboowa G, et al. The
465		evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding
466		genomic surveillance. Science [Internet]. 2022 Oct 7 [cited 2023 Jun
467		5];378(6615). Available from: /pmc/articles/PMC9529057/
468	5.	Hosch S, Mpina M, Nyakurungu E, Borico NS, Obama TMA, Ovona MC, et al.
469		Genomic Surveillance Enables the Identification of Co-infections With Multiple
470		SARS-CoV-2 Lineages in Equatorial Guinea. Front Public Heal.
471		2022;9(January):1-7.
472	6.	Ozer EA, Simons LM, Adewumi OM, Fowotade AA, Omoruyi EC, Adeniji JA,
473		et al. Multiple expansions of globally uncommon SARS-CoV-2 lineages in
474		Nigeria. Nat Commun. 2022;13(1).
475	7.	MINSABS. Ministerio de Sanidad y Bienestar Social-Guinea Equatorial
476		[Internet]. [cited 2023 Apr 23]. Available from:
477		https://guineasalud.org/estadisticas/
478	8.	Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data –
479		from vision to reality. Eurosurveillance [Internet]. 2017 Mar 3 [cited 2023 Aug

480		22];22(13):1. Available from: /pmc/articles/PMC5388101/
481	9.	World Health Organization. Scaling up genomic sequencing in Africa [Internet].
482		Available from: https://www.afro.who.int/news/scaling-genomic-sequencing-
483		africa
484	10.	Uwishema O, Badri R, Onyeaka H, Okereke M, Akhtar S, Mhanna M, et al.
485		Fighting Tuberculosis in Africa: The Current Situation Amidst the COVID-19
486		Pandemic. Disaster Med Public Health Prep [Internet]. 2022 [cited 2023 Jul 3];
487		Available from: https://pubmed.ncbi.nlm.nih.gov/35673793/
488	11.	Shi B, Zheng J, Xia S, Lin S, Wang X, Liu Y, et al. Accessing the syndemic of
489		COVID-19 and malaria intervention in Africa. Infect Dis poverty [Internet]. 2021
490		Dec 1 [cited 2023 Jul 3];10(1). Available from:
491		https://pubmed.ncbi.nlm.nih.gov/33413680/
492	12.	Uwishema O, Sapkota S, Wellington J, Onyeaka CVP, Onyeaka H.
493		Leishmaniasis control in the light of the COVID-19 pandemic in Africa. Ann
494		Med Surg [Internet]. 2022 Aug 1 [cited 2023 Jul 3];80:104263. Available from:
495		/pmc/articles/PMC9339101/
496	13.	(WHO) WHO. World malaria report 2022. Geneva; 2022.
497	14.	World Health Organization. The potential impact of health service disruptions on
498		the burden of malaria: a modelling analysis for countries in sub-Saharan Africa
499		[Internet]. 2020. 29 p. Available from:
500		https://www.who.int/publications/i/item/9789240004641
501	15.	López-Farfán D, Yerbanga RS, Parres-Mercader M, Torres-Puente M, Gómez-
502		Navarro I, Sanou DMS, et al. Prevalence of SARS-CoV-2 and co-infection with
503		malaria during the first wave of the pandemic (the Burkina Faso case). Front
504		Public Heal [Internet]. 2022 Dec 12 [cited 2023 Jan 18];10. Available from:

505		/pmc/articles/PMC9791192/
506	16.	Amoo OS, Aina OO, Okwuraiwe AP, Onwuamah CK, Shaibu JO, Ige F, et al.
507		COVID-19 Spread Patterns Is Unrelated to Malaria Co-Infections in Lagos,
508		Nigeria. Adv Infect Dis. 2020;10(05):200–15.
509	17.	Muhammad Y, Aminu YK, Ahmad AE, Iliya S, Muhd N, Yahaya M, et al. An
510		elevated 8-isoprostaglandin F2 alpha (8-iso-PGF2 $\alpha$ ) in COVID-19 subjects co-
511		infected with malaria. Pan Afr Med J [Internet]. 2020 Sep 21 [cited 2022 Sep
512		15];37(78):1–10. Available from: /pmc/articles/PMC7680236/
513	18.	Onosakponome EO, Wogu MN. The Role of Sex in Malaria-COVID19
514		Coinfection and Some Associated Factors in Rivers State, Nigeria. J Parasitol
515		Res. 2020;2020.
516	19.	Matangila JR, Nyembu RK, Telo GM, Ngoy CD, Sakobo TM, Massolo JM, et al.
517		Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema,
518		a public hospital in Kinshasa, in the Democratic Republic of Congo: A
519		retrospective cohort study. PLoS One [Internet]. 2020;15(12 December):1-15.
520		Available from: http://dx.doi.org/10.1371/journal.pone.0244272
521	20.	Achan J, Serwanga A, Wanzira H, Kyagulanyi T, Nuwa A, Magumba G, et al.
522		Current malaria infection, previous malaria exposure, and clinical profiles and
523		outcomes of COVID-19 in a setting of high malaria transmission: an exploratory
524		cohort study in Uganda. The Lancet Microbe [Internet]. 2022;3(1):e62-71.
525		Available from: http://dx.doi.org/10.1016/S2666-5247(21)00240-8
526	21.	Bakamutumaho B, Cummings MJ, Owor N, Kayiwa J, Namulondo J,
527		Byaruhanga T, et al. Severe COVID-19 in uganda across two epidemic phases: A
528		prospective cohort study. Am J Trop Med Hyg. 2021;105(3):740-4.
529	22.	Morton B, Barnes KG, Anscombe C, Jere K, Matambo P, Mandolo J, et al.

530		Distinct clinical and immunological profiles of patients with evidence of SARS-
531		CoV-2 infection in sub-Saharan Africa. Nat Commun. 2021;12(1).
532	23.	Hussein R, Guedes M, Ibraheim N, Ali MM, El-Tahir A, Allam N, et al. Impact
533		of COVID-19 and malaria coinfection on clinical outcomes: a retrospective
534		cohort study. Clin Microbiol Infect. 2022 Aug 1;28(8):1152.e1-1152.e6.
535	24.	Ditombi BCM, Ngondza BP, Boulingui CM, Nguema OAM, Ngomo JMN,
536		M'Bondoukwé NP, et al. Malaria and COVID-19 prevalence in a population of
537		febrile children and adolescents living in Libreville. South African J Infect Dis
538		[Internet]. 2022 Oct 26 [cited 2023 Jun 7];37(1). Available from:
539		/pmc/articles/PMC9634652/
540	25.	Sebastião CS, Gaston C, Paixão JP, Euclides  , Sacomboio NM, Neto Z, et al.
541		Coinfection between SARS-CoV-2 and vector-borne diseases in Luanda, Angola.
542		2021 [cited 2023 Jun 15]; Available from:
543		https://onlinelibrary.wiley.com/doi/10.1002/jmv.27354
544	26.	Ingabire PM, Nantale R, Sserwanja Q, Nakireka S, Musaba MW, Muyinda A, et
545		al. Factors associated with prolonged hospitalization of patients with corona virus
546		disease (COVID-19) in Uganda: a retrospective cohort study. Trop Med Health
547		[Internet]. 2022 Dec 1 [cited 2023 Jun 16];50(1):100. Available from:
548		/pmc/articles/PMC9795158/
549	27.	Mahajan NN, Gajbhiye RK, Bahirat S, Lokhande PD, Mathe A, Rathi S, et al.
550		Co-infection of malaria and early clearance of SARS-CoV-2 in healthcare
551		workers. J Med Virol. 2021;93(4):2431-8.
552	28.	WHO. Malaria Microscopy Quality Assurance Manual. 2009;
553	29.	Grubaugh ND, Gangavarapu K, Quick J, Matteson NL, De Jesus JG, Main BJ, et
554		al. An amplicon-based sequencing framework for accurately measuring intrahost

555		virus diversity using PrimalSeq and iVar. Genome Biol [Internet]. 2019 Jan 8
556		[cited 2022 Sep 16];20(1):1–19. Available from:
557		https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1618-7
558	30.	Wood DE, Salzberg SL. Kraken: Ultrafast metagenomic sequence classification
559		using exact alignments. Genome Biol [Internet]. 2014 Mar 3 [cited 2022 Sep
560		16];15(3):1–12. Available from:
561		https://genomebiology.biomedcentral.com/articles/10.1186/gb-2014-15-3-r46
562	31.	Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ
563		preprocessor. Bioinformatics [Internet]. 2018 Sep 9 [cited 2022 Sep
564		16];34(17):i884. Available from: /pmc/articles/PMC6129281/
565	32.	Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: summarize analysis
566		results for multiple tools and samples in a single report. Bioinformatics [Internet].
567		2016 Oct 1 [cited 2022 Sep 16];32(19):3047-8. Available from:
568		https://academic.oup.com/bioinformatics/article/32/19/3047/2196507
569	33.	Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus
570		associated with human respiratory disease in China. Nat 2020 5797798 [Internet].
571		2020 Feb 3 [cited 2022 Sep 16];579(7798):265–9. Available from:
572		https://www.nature.com/articles/s41586-020-2008-3
573	34.	Katoh K, Standley DM. MAFFT Multiple Sequence Alignment Software Version
574		7: Improvements in Performance and Usability. Mol Biol Evol [Internet]. 2013
575		Apr 1 [cited 2022 Sep 16];30(4):772–80. Available from:
576		https://academic.oup.com/mbe/article/30/4/772/1073398
577	35.	O'Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al.
578		Assignment of epidemiological lineages in an emerging pandemic using the
579		pangolin tool. Virus Evol [Internet]. 2021 [cited 2022 Sep 16];7(2). Available

580		from: /pmc/articles/PMC8344591/
581	36.	Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment,
582		mutation calling and quality control for viral genomes. J Open Source Softw
583		[Internet]. 2021 Nov 30 [cited 2022 Sep 16];6(67):3773. Available from:
584		https://joss.theoj.org/papers/10.21105/joss.03773
585	37.	Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al.
586		NextStrain: Real-time tracking of pathogen evolution. Bioinformatics. 2018 Dec
587		1;34(23):4121–3.
588	38.	Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood
589		phylodynamic analysis. Virus Evol [Internet]. 2018 Jan 1 [cited 2022 Sep
590		16];4(1). Available from: /pmc/articles/PMC5758920/
591	39.	Martínez-Martínez FJ, Massinga AJ, De Jesus Á, Ernesto RM, Cano-Jiménez P,
592		Chiner-Oms Á, et al. Tracking SARS-CoV-2 introductions in Mozambique using
593		pandemic-scale phylogenies: a retrospective observational study. Lancet Glob
594		Heal. 2023;11(6):e933-41.
595	40.	Turakhia Y, Thornlow B, Hinrichs AS, Maio N, Gozashti L, Lanfear R, et al.
596		Ultrafast Sample placement on Existing tRees (UShER) enables real-time
597		phylogenetics for the SARS-CoV-2 pandemic. Nat Genet [Internet]. [cited 2023
598		Aug 23]; Available from: https://doi.org/10.1038/s41588-021-00862-7
599	41.	Lanfear R. Global phylogenies of SARS-CoV-2 sequences [Internet]. Available
600		from: https://github.com/roblanf/sarscov2phylo
601	42.	Thornlow B. matUtils [Internet]. Available from: https://usher-
602		wiki.readthedocs.io/en/latest/matUtils.html
603	43.	Sanderson T. Taxonium, a web-based tool for exploring large phylogenetic trees
604		eLife 11:e82392. Elife [Internet]. 2022;11:e82392. Available from:

605		https://doi.org/10.7554/eLife.82392%0A
606	44.	Kusi KA, Frimpong A, Partey FD, Lamptey H, Amoah LE, Ofori MF. High
607		infectious disease burden as a basis for the observed high frequency of
608		asymptomatic SARS-CoV-2 infections in sub-Saharan Africa. AAS Open Res.
609		2021;4(May):2.
610	45.	Hussein MIH, Albashir AAD, Elawad OAMA, Homeida A. Malaria and
611		COVID-19: unmasking their ties. Malar J [Internet]. 2020;19(1):1-10. Available
612		from: https://doi.org/10.1186/s12936-020-03541-w
613	46.	Osei SA, Biney RP, Anning AS, Nortey LN, Ghartey-Kwansah G. Low
614		incidence of COVID-19 case severity and mortality in Africa; Could malaria co-
615		infection provide the missing link? BMC Infect Dis [Internet]. 2022;22(1):1–11.
616		Available from: https://doi.org/10.1186/s12879-022-07064-4
617	47.	Iesa MAM, Osman MEM, Hassan MA, Dirar AIA, Abuzeid N, Mancuso JJ, et al.
618		SARS-CoV-2 and Plasmodium falciparum common immunodominant regions
619		may explain low COVID-19 incidence in the malaria-endemic belt. New
620		microbes new Infect [Internet]. 2020 Nov 1 [cited 2022 Jul 7];38. Available
621		from: https://pubmed.ncbi.nlm.nih.gov/33230417/
622	48.	Raham TF. Influence of malaria endemicity and tuberculosis prevalence on
623		COVID-19 mortality. Public Health [Internet]. 2021;194:33-5. Available from:
624		https://doi.org/10.1016/j.puhe.2021.02.018
625	49.	Johns Hopkins University. Johns Hopkins coronavirus resource center [Internet].
626		[cited 2023 Jul 10]. Available from:
627		https://coronavirus.jhu.edu/region/equatorial-guinea
628	50.	Wilkinson E, Giovanetti M, Tegally H, San JE, Lessells R, Cuadros D, et al. A
629		year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded

630	in Africa. Scie	ence (80-).	. 2021;374(	6566):423-31.
-----	-----------------	-------------	-------------	---------------

- 631 51. cov-lineages.org [Internet]. Available from: https://cov-
- 632 lineages.org/lineage\_list.html
- 633 52. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, et al.
- 634 SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nat 2021
- 635 5997883 [Internet]. 2021 Sep 6 [cited 2023 Jun 5];599(7883):114–9. Available
- 636 from: https://www.nature.com/articles/s41586-021-03944-y
- 637 53. Martínez-Martínez J, Cano-Jiménez P, Chiner-Oms Á, Bsc G-N, Guillot-
- 638 Fernández M, Jiménez-Serrano S, et al. Tracking SARS-CoV-2 introductions in
- 639 Mozambique using pandemic-scale phylogenies: a retrospective observational
- study. Artic Lancet Glob Heal [Internet]. 2023 [cited 2023 Aug 23];11:933–74.

641 Available from: https://gitlab.

- 642 54. López-Farfán D, Irigoyen N, Gómez-Díaz E. Exploring SARS-CoV-2 and
- 643 Plasmodium falciparum coinfection in human erythrocytes. Front Immunol
- 644 [Internet]. 2023 Mar 13 [cited 2023 Jun 5];14. Available from:
- 645 https://pubmed.ncbi.nlm.nih.gov/36993979/
- 646 55. Huerga Encabo H, Grey W, Garcia-Albornoz M, Wood H, Ulferts R, Aramburu
- 647 IV, et al. Human Erythroid Progenitors Are Directly Infected by SARS-CoV-2:
- 648 Implications for Emerging Erythropoiesis in Severe COVID-19 Patients. Stem
- 649 cell reports [Internet]. 2021 Mar 9 [cited 2022 Aug 10];16(3):428–36. Available
- 650 from: https://pubmed.ncbi.nlm.nih.gov/33581053/
- 56. Shahbaz S, Xu L, Osman M, Sligl W, Shields J, Joyce M, et al. Erythroid
- precursors and progenitors suppress adaptive immunity and get invaded by
- 653 SARS-CoV-2. Stem Cell Reports. 2021 May 11;16(5):1165–81.

# 655 Supporting information

- 656 S1 Text. Tables S1 to S5
- 657 S6 Table. Genome-based epidemiological analysis of the sequenced samples









